COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock24/06/2025
-   
  SeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving Therapy24/06/2025
-   
  Innovate GBM Rings the NASDAQ Closing Bell in Honor of Brain Tumor Patients and Community24/06/2025
-   
  Celia Huber Joins AMN Healthcare Board of Directors24/06/2025
-   
  Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting24/06/2025
-   
  Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program24/06/2025
-   
  Green Tree Pediatrics is Now Part of the Zarminali Pediatrics, Signaling New Chapter of Care and Community Commitment24/06/2025
-   
  CareMore Health Announces Appointment of Sam Wald as Chief Executive Officer24/06/2025
-   
  Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy24/06/2025
-   
  Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference24/06/2025
-   
  Journey Medical to Join Russell 2000® and Russell 3000® Indexes24/06/2025
-   
  Xenon Announces Appointment of Darren Cline as Chief Commercial Officer24/06/2025
-   
  CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer24/06/2025
-   
  Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation24/06/2025
-   
  THC Therapeutics, Inc. Announces Acquisition of Oregon and California Consortium of Cannabis Companies24/06/2025
-   
  Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement24/06/2025
-   
  Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)24/06/2025
-   
  Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome24/06/2025
-   
  OneMedNet Announces Additional $3.7 Million of Funding in Private Placement Transactions and Approximately $11 Million in Reductions in Liabilities24/06/2025
Pages